S&P 500   3,378.71 (+1.30%)
DOW   27,885.27 (+1.58%)
QQQ   279.40 (+1.25%)
AAPL   115.86 (+1.55%)
MSFT   210.91 (+1.76%)
FB   264.94 (+1.20%)
GOOGL   1,478.71 (+0.87%)
AMZN   3,202.00 (+1.82%)
TSLA   427.99 (+2.13%)
NVDA   541.40 (+2.34%)
BABA   291.66 (+5.32%)
CGC   14.66 (+1.10%)
MU   48.21 (-4.93%)
GE   6.24 (+1.96%)
AMD   82.17 (+0.49%)
T   28.45 (+0.53%)
F   6.65 (+0.76%)
ACB   4.76 (+1.71%)
GILD   62.79 (+1.11%)
NFLX   499.37 (+1.19%)
DIS   124.41 (-0.79%)
BA   166.85 (+1.99%)
BAC   24.03 (+1.09%)
S&P 500   3,378.71 (+1.30%)
DOW   27,885.27 (+1.58%)
QQQ   279.40 (+1.25%)
AAPL   115.86 (+1.55%)
MSFT   210.91 (+1.76%)
FB   264.94 (+1.20%)
GOOGL   1,478.71 (+0.87%)
AMZN   3,202.00 (+1.82%)
TSLA   427.99 (+2.13%)
NVDA   541.40 (+2.34%)
BABA   291.66 (+5.32%)
CGC   14.66 (+1.10%)
MU   48.21 (-4.93%)
GE   6.24 (+1.96%)
AMD   82.17 (+0.49%)
T   28.45 (+0.53%)
F   6.65 (+0.76%)
ACB   4.76 (+1.71%)
GILD   62.79 (+1.11%)
NFLX   499.37 (+1.19%)
DIS   124.41 (-0.79%)
BA   166.85 (+1.99%)
BAC   24.03 (+1.09%)
S&P 500   3,378.71 (+1.30%)
DOW   27,885.27 (+1.58%)
QQQ   279.40 (+1.25%)
AAPL   115.86 (+1.55%)
MSFT   210.91 (+1.76%)
FB   264.94 (+1.20%)
GOOGL   1,478.71 (+0.87%)
AMZN   3,202.00 (+1.82%)
TSLA   427.99 (+2.13%)
NVDA   541.40 (+2.34%)
BABA   291.66 (+5.32%)
CGC   14.66 (+1.10%)
MU   48.21 (-4.93%)
GE   6.24 (+1.96%)
AMD   82.17 (+0.49%)
T   28.45 (+0.53%)
F   6.65 (+0.76%)
ACB   4.76 (+1.71%)
GILD   62.79 (+1.11%)
NFLX   499.37 (+1.19%)
DIS   124.41 (-0.79%)
BA   166.85 (+1.99%)
BAC   24.03 (+1.09%)
S&P 500   3,378.71 (+1.30%)
DOW   27,885.27 (+1.58%)
QQQ   279.40 (+1.25%)
AAPL   115.86 (+1.55%)
MSFT   210.91 (+1.76%)
FB   264.94 (+1.20%)
GOOGL   1,478.71 (+0.87%)
AMZN   3,202.00 (+1.82%)
TSLA   427.99 (+2.13%)
NVDA   541.40 (+2.34%)
BABA   291.66 (+5.32%)
CGC   14.66 (+1.10%)
MU   48.21 (-4.93%)
GE   6.24 (+1.96%)
AMD   82.17 (+0.49%)
T   28.45 (+0.53%)
F   6.65 (+0.76%)
ACB   4.76 (+1.71%)
GILD   62.79 (+1.11%)
NFLX   499.37 (+1.19%)
DIS   124.41 (-0.79%)
BA   166.85 (+1.99%)
BAC   24.03 (+1.09%)
Log in
OTCMKTS:RCPIQ

Rock Creek Pharmaceuticals Stock Forecast, Price & News

$0.0016
0.00 (0.00 %)
(As of 09/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.01
Volume175 shs
Average Volume758,290 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta3.45
Rock Creek Pharmaceuticals, Inc., a pharmaceutical development company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its lead compound is Anatabine citrate, a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs available, such as biologics, steroids, and non-steroidal anti-inflammatories. The company was formerly known as Star Scientific, Inc. and changed its name to Rock Creek Pharmaceuticals, Inc. in June 2014. Rock Creek Pharmaceuticals, Inc. is headquartered in Sarasota, Florida. On September 27, 2016, Rock Creek Pharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RCPIQ
Previous SymbolNASDAQ:RCPI
CUSIPN/A
Phone844-727-0727

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees5
Next Earnings DateN/A
OptionableNot Optionable
$0.0016
0.00 (0.00 %)
(As of 09/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RCPIQ News and Ratings via Email

Sign-up to receive the latest news and ratings for RCPIQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Frequently Asked Questions

How has Rock Creek Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Rock Creek Pharmaceuticals' stock was trading at $0.0005 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RCPIQ shares have increased by 220.0% and is now trading at $0.0016.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Rock Creek Pharmaceuticals?

Rock Creek Pharmaceuticals saw a decrease in short interest in the month of August. As of August 14th, there was short interest totaling 200 shares, a decrease of 99.5% from the July 30th total of 39,700 shares. Based on an average daily volume of 631,300 shares, the days-to-cover ratio is presently 0.0 days.
View Rock Creek Pharmaceuticals' Short Interest
.

Who are some of Rock Creek Pharmaceuticals' key competitors?

Who are Rock Creek Pharmaceuticals' key executives?

Rock Creek Pharmaceuticals' management team includes the following people:
  • Dr. Michael John Mullan MBBS (M.D., ), Ph.D., Chairman, Chief Exec. Officer and Pres (Age 62)
  • Dr. Curtis Wright IV, Sr. VP and Medical & Clinical Director (Age 70)

What is Rock Creek Pharmaceuticals' stock symbol?

Rock Creek Pharmaceuticals trades on the OTCMKTS under the ticker symbol "RCPIQ."

How do I buy shares of Rock Creek Pharmaceuticals?

Shares of RCPIQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rock Creek Pharmaceuticals' stock price today?

One share of RCPIQ stock can currently be purchased for approximately $0.00.

What is Rock Creek Pharmaceuticals' official website?

The official website for Rock Creek Pharmaceuticals is www.rockcreekpharmaceuticals.com.

How can I contact Rock Creek Pharmaceuticals?

Rock Creek Pharmaceuticals' mailing address is 2040 WHITFIELD AVE. SUITE 300, SARASOTA FL, 34243. The company can be reached via phone at 844-727-0727 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.